PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Some net income increase while GNPX is negative at -773.37%. John Neff would see a short-term edge over the struggling competitor.
7.12%
Less D&A growth vs. GNPX's 23.65%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
Negative yoy SBC while GNPX is 1378.28%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-21.66%
Both reduce yoy usage, with GNPX at -233.35%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both negative yoy AP, with GNPX at -263.19%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
161.21%
Some yoy usage while GNPX is negative at -40.71%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
200.00%
Some yoy increase while GNPX is negative at -100.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
22.87%
Some CFO growth while GNPX is negative at -1426.85%. John Neff would note a short-term liquidity lead over the competitor.
-183.51%
Both yoy lines negative, with GNPX at -116.62%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
Both yoy lines negative, with GNPX at -116.62%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
Negative yoy issuance while GNPX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.